美国新关税有可能增加成本,并扰乱94%的生物技术公司的供应链。 New US tariffs threaten to raise costs and disrupt supply chains for 94% of biotech firms.

美国对来自欧盟、中国和加拿大的进口关税可以大幅提高生物技术工业的制造成本,94%的公司预期成本会更高。 US tariffs on imports from the EU, China, and Canada could significantly increase manufacturing costs for the biotech industry, with 94% of firms expecting higher expenses. 这可能扰乱供应链,迫使公司寻找新的供应商或转移制造业,这一过程需要长达两年。 This could disrupt supply chains and force companies to find new suppliers or relocate manufacturing, a process that takes up to two years. 关税还可能阻碍投资,减少研发预算,影响临床试验的地点,由于成本和监管效率降低,可能有利于欧洲。 The tariffs may also deter investment, reduce R&D budgets, and influence the location of clinical trials, potentially favoring Europe due to lower costs and regulatory efficiency. 制药公司正在探索国内制造业,但这需要大量资本和时间,可能导致短期供应问题。 Pharmaceutical companies are exploring domestic manufacturing, but this requires substantial capital and time, leading to potential short-term supply issues.